2575 Xuanzhu Biopharmaceutical Co., Ltd. HKEX · China

Xuanzhu Biopharmaceutical Co. (2575) news

Xuanzhu Biopharmaceutical Co., Ltd. is a public biotech or pharmaceutical company listed on HKEX under the ticker 2575, recorded under China. The directory classifies it as Biotechnology / therapeutics. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Xuanzhu Biopharmaceutical Co. news

We have not published a story on Xuanzhu Biopharmaceutical Co. yet. When there is news, it will appear here.

Questions about Xuanzhu Biopharmaceutical Co.

What is the ticker symbol of Xuanzhu Biopharmaceutical Co.?

Xuanzhu Biopharmaceutical Co., Ltd. trades under the ticker 2575 on HKEX.

Where is Xuanzhu Biopharmaceutical Co. listed?

Xuanzhu Biopharmaceutical Co., Ltd. is listed on HKEX.

Which country or territory is Xuanzhu Biopharmaceutical Co. listed under?

Our directory records Xuanzhu Biopharmaceutical Co., Ltd. under China.

What does Xuanzhu Biopharmaceutical Co. do?

Our directory classifies Xuanzhu Biopharmaceutical Co., Ltd. as: Biotechnology / therapeutics. This is a directory classification, not a description of the pipeline.

What is the ISIN of Xuanzhu Biopharmaceutical Co.?

The ISIN recorded for Xuanzhu Biopharmaceutical Co., Ltd. is CNE1000074Q1.

Does aibio.space cover Xuanzhu Biopharmaceutical Co.?

aibio.space lists Xuanzhu Biopharmaceutical Co., Ltd. among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to Xuanzhu Biopharmaceutical Co.?

Companies in our directory listed in the same country and business area as Xuanzhu Biopharmaceutical Co.: Biocytogen Pharmaceuticals (Beijing) Co., Beijing Konruns Pharmaceutical Co., Ocumension Therapeutics, Dizal Pharmaceutical Co, Kingchem (Liaoning) Life Science Co., Xiamen Kingdomway Group Co..

Investor discussion: Xuanzhu Biopharmaceutical Co.

Members talk about Xuanzhu Biopharmaceutical Co. (2575). Reader posts, not aibio.space reporting, and not investment advice.

Rules

Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Xuanzhu Biopharmaceutical Co., newest first. Each line links the filing it comes from.

Jul 19, 2026Legal
Legal proceedings: VOLUNTARY ANNOUNCEMENT ARBITRATION AWARD AGAINST THE COMPANY. Source
May 27, 2026Financings
Share or debt issue: CIRCULAR FOR THE 2025 ANNUAL GENERAL MEETING. Source
Oct 5, 2025Financings
Share or debt issue: GLOBAL OFFERING. Source

Press releases

Headlines of Xuanzhu Biopharmaceutical Co.'s own announcements, newest first. Each opens the full release on the newswire that carried it.

Oct 21, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT PHASE III CLINICAL STUDY DATA OF ANAPRAZOLE SODIUM FOR REFLUX ESOPHAGITIS PRESENTED AT UEG WEEK 2026PRESENTED AT UEG WEEK 2026
Sep 17, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT UNUSUAL PRICE MOVEMENTS
Sep 16, 2026HKEXnews
2025 ANNUAL REPORT - SUPPLEMENTAL INFORMATION
Sep 3, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT COMMERCIAL COOPERATION WITH INNOBIC FOR BIREOCICLIB IN THE THAILAND MARKET
Aug 26, 2026HKEXnews
ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2026
Jul 19, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT ARBITRATION AWARD AGAINST THE COMPANY
Jun 30, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT NDA ACCEPTED BY NMPA FOR THE NEW INDICATION OF ANAPRAZOLE SODIUM FOR THE TREATMENT OF REFLUX ESOPHAGITIS
Jun 21, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT FIRST PATIENT ENROLLED IN PHASE III CLINICAL TRIAL OF ANAPRAZOLE SODIUM FOR HELICOBACTER PYLORI ERADICATION
Jun 18, 2026HKEXnews
ELECTION OF EMPLOYEE REPRESENTATIVE DIRECTOR
Jun 18, 2026HKEXnews
ARTICLES OF ASSOCIATION
Jun 18, 2026HKEXnews
POLL RESULTS OF THE 2025 ANNUAL GENERAL MEETING AND ABOLISHMENT OF THE SUPERVISORY COMMITTEE AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION
May 27, 2026HKEXnews
NOTICE OF THE 2025 ANNUAL GENERAL MEETING
May 27, 2026HKEXnews
CIRCULAR FOR THE 2025 ANNUAL GENERAL MEETING
May 26, 2026HKEXnews
PROPOSED AMENDMENT TO THE ARTICLES OF ASSOCIATION, ABOLITION OF THE SUPERVISORY COMMITTEE AND CHANGE OF BOARD COMPOSITION
May 12, 2026HKEXnews
INSIDE INFORMATION COMPLETION OF THE H SHARE FULL CIRCULATION BY THE COMPANY
Apr 27, 2026HKEXnews
Letter to Non-Registered Shareholders - Reminder letter regarding the Arrangement of Electronic Dissemination of Corporate Communications and Reply Form
Apr 27, 2026HKEXnews
Letter to Registered Shareholders - Reminder letter regarding the Arrangement of Electronic Dissemination of Corporate Communications and Reply Form
Apr 20, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT RESULTS OF PRELIMINARY DATA FROM THE PHASE 1B FORTRESS CLINICAL STUDY OF NG-350A PRESENTED AT THE 2026 AACR
Apr 19, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT RESULTS OF PHASE III CLINICAL DATA OF DIROZALKIB FOR THE FIRST-LINE TREATMENT OF ALK POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER PRESENTED AT THE 2026 AACR
Apr 17, 2026HKEXnews
INSIDE INFORMATION APPROVAL BY THE STOCK EXCHANGE REGARDING THE APPLICATION FOR THE PROPOSED IMPLEMENTATION OF H SHARE FULL CIRCULATION

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open HKEX:2575 on TradingView.

Listing details

Company: Xuanzhu Biopharmaceutical Co., Ltd.
Ticker: 2575
Listing: HKEX
Country or territory: China
Business scope: Biotechnology / therapeutics
ISIN: CNE1000074Q1
Last quote in directory: 2026-10-22
Directory source: Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction